A decision by Canada’s Drug Agency will make it more difficult for Canadians to access a drug shown to slow Alzheimer’s disease in some people, says an Ottawa cognitive neurologist and researcher.

Americans are having a few regrets about their approach to child safety in the care of drug-using parents. Earlier this month, Gov. Michelle Lujan Grisham of New Mexico said she never should have ...

GLP-1 medications are everywhere, but what happens when appetite suppression meets a culture obsessed with thinness?

The recommendations are not binding but offer the legislature a guide to what laws Alaska would need to offer care if ...

Rare diseases are not actually that rare. Collectively they affect 500 million people around the world. Some, such as Huntington’s disease and sickle cell disease, affect many thousands, others only ...

ViiV Healthcare presents data for two investigational HIV treatment therapies with potential for twice-yearly dosing: London Saturday, February 28, 2026, 13:00 Hrs [IST] ViiV Heal ...

The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP over the weekly dosing intervalCommercial availability expected during early part of Q2 2026Rare Pedia ...

Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics ...